Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wasan

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Journal of Cancer|November 28, 2019
Jiedu Sangen Decoction Reverses Epithelial-to-mesenchymal Transition and Inhibits Invasion and Metastasis of Colon Cancer via AKT/GSK-3β Signaling PathwayLi Yuan, Kai Zhang, Meng-Meng Zhou, et al.
Physics in Medicine and Biology|January 15, 2010
Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studiesKatherine R Gray, Kaiyumars B Contractor, Laura M Kenny, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 17, 2024
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyAndrew S Kennedy, Daniel B Brown, Marwan Fakih, et al.
ESMO Open|August 11, 2018
PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancerStephen P Pereira, Mark Jitlal, Marian Duggan, et al.
ESMO Open|December 25, 2021
Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapyP J Ross, H S Wasan, D Croagh, et al.
The Lancet. Oncology|February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Journal of Clinical and Experimental Hepatology|April 27, 2019
Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a Risk Factor for CholangiocarcinomaChristopher A Wadsworth, Peter H Dixon, Simon Taylor-Robinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Journal of Cancer|November 28, 2019
Jiedu Sangen Decoction Reverses Epithelial-to-mesenchymal Transition and Inhibits Invasion and Metastasis of Colon Cancer via AKT/GSK-3β Signaling PathwayLi Yuan, Kai Zhang, Meng-Meng Zhou, et al.
Physics in Medicine and Biology|January 15, 2010
Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studiesKatherine R Gray, Kaiyumars B Contractor, Laura M Kenny, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 17, 2024
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyAndrew S Kennedy, Daniel B Brown, Marwan Fakih, et al.
ESMO Open|August 11, 2018
PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancerStephen P Pereira, Mark Jitlal, Marian Duggan, et al.
ESMO Open|December 25, 2021
Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapyP J Ross, H S Wasan, D Croagh, et al.
The Lancet. Oncology|February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Journal of Clinical and Experimental Hepatology|April 27, 2019
Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a Risk Factor for CholangiocarcinomaChristopher A Wadsworth, Peter H Dixon, Simon Taylor-Robinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Pageof 9